

# Successful management of uterine fibroids by Ayurvedic treatment

## Abstract

Uterine fibroids are the most common solid benign tumours in women of reproductive age. Uterine fibroid-related symptoms negatively impact physical and social activities, women's health-related quality of life, and work productivity. A 36-year-old female patient approached the outpatient department with complaints of menorrhagia and low back ache. Ultrasound scan revealed small intramural anterior wall fibroid measuring 13\*15mm. She was suggested hysterectomy for the same; however, the patient was not willing to undergo surgery and was in quest of nonhormonal treatment. She was treated as per the Ayurvedic line of treatment of asrugdhara which is correlated to Menorrhagia (presenting complaint). She was administered Asokarishta, Chandraprabha vati and Pushyanuga churna tablets available in the Outpatient department. Treatment was continued for 6 months with a follow up once in 15 days and a repeat scan revealed shrinking size of the fibroid and relief in symptoms. Patient was willing to continue the medication for another 3 months till all her symptoms subsided. A follow up scan also revealed that the fibroids had disappeared. During the treatment period patient has not reported any negative effects concerning the progression of disease nor regarding the medicines. An attempt has been made to present the successful management of fibroid with non-hormonal medicines in a patient of mid-thirties. This paper intends to instill confidence among Ayurvedic practitioners regarding the safe, noninvasive, non-hormonal cost-effective management of fibroids through Ayurvedic interventions.

**Keywords:** asrugdhara, fibroid, uterine fibroid, leiomyomas, fibromyoma, uterine fibroid

Volume 12 Issue 6 - 2019

**Shubhashree MN, Doddamani SH, Bhavya BM, Bharali BK**

Research Office, Regional Ayurveda Research Institute for Metabolic disorders (RARIMD)

**Correspondence:** Shubhashree MN, Research Officer, Regional Ayurveda Research Institute for Metabolic disorders (RARIMD), Clinical Research Unit, P.C.Road, Bangalore, India, Tel 9448016968, Email shubhathejas@gmail.com

**Received:** June 24, 2019 | **Published:** December 11, 2019

## Introduction

Fibroids occur in 20-40% of women during reproductive age and 11-19% in perimenopausal age.<sup>1</sup> They are clinically apparent in up to 25% of women and cause significant morbidity, including prolonged or heavy menstrual bleeding, pelvic pressure or pain, and, in rare cases, reproductive dysfunction.<sup>2</sup> Women experience distress and impaired work productivity due to fibroid. There are many women undiagnosed with significant symptoms emphasizing the need for improved awareness and management of fibroids.<sup>3</sup>

Uterine myomas have been classified according to their general uterine position: submucous, intramural, and subserosal. Intramural fibroids are located within the wall of the uterus and are the most common type; unless they may be asymptomatic. Though the exact cause of intramural fibroids is unknown, it is believed that fibroids develop from an abnormal muscle cell in the middle layer of the uterine wall. It rapidly multiplies and forms a tumor being influenced by estrogen.<sup>4</sup> Traditionally, myomas have been the leading cause for hysterectomy, making this surgery the third most common surgical intervention worldwide. Removal of the uterus is unacceptable to women desirous of (further) child bearing though it offers a definitive solution to the problem. Newer procedures for fibroid removal may relieve symptoms, but duration of symptom relief and efficacy of the procedures in restoring fertility have not been evaluated. Such procedures include High-intensity focused sonography, Cryotherapy, Radiofrequency ablation, Magnetic resonance-guided focused ultrasound surgery; Anti-hormonal drugs like progestin or danazol block estrogen to treat fibroids. Uterine fibroid embolization (UFE) gonadotrophin-releasing hormone (GnRH) agonists and selective

progesterone receptor modulators are some of the other treatment options for fibroid. While oral contraceptive pills have been used to treat fibroid related symptoms such as bleeding and dysmenorrhoea, their effect is usually based on their suppression/regulation of the menstrual cycle. The effect of ethinyl – estrogen/progesterone containing pills on myoma growth is less clear. Mirena, is one of the widely used levonorgestrel intrauterine devices, most commonly used in fibroid. Even though the bleeding and dysmenorrhoea-related symptoms are treated, the actual myoma size remains largely unchanged.<sup>5</sup>

The condition of uterine fibroid is similar to Garbhashayagatagranthi, mentioned in Ayurveda with vitiated vata affecting mamsa (muscle tissue), rakta (blood) and medas (fat) mixed with kapha producing rounded, protuberant, knotty and hard swelling. Fibroids can be related to the “Granthi” mentioned in Ayurvedic texts, and it can be managed according to the principle of Samprapti Vighatana (to break the pathogenesis).<sup>6</sup>

## Case study

A 36-year-old female patient, a home maker, reported to the outpatient department of Regional Ayurveda Research Institute for Metabolic Disorders on 22<sup>nd</sup> February 2016 with complaints of low back ache and painful heavy menstrual bleeding since 1 year. She gave a history of irregular, heavy flow for 7 to 8 days during each menstrual cycle. She was gravida 1, was nonvegetarian & had a less active lifestyle. She was diagnosed as having Fibroid from the prior reports and was advised hysterectomy. No other systemic complaints or family history related to this condition were significant. Past history seems to be insignificant.

## Clinical findings

### General examination (RogiPariksha)

All vitals were stable on examination and it was assessed that the patient belonged to Pitta-vatajaprakruti. Per abdomen examination revealed that abdomen was soft, non-tender and no organomegaly was detected.

### Investigation

Ultrasound scan of Abdomen & Pelvis revealed that uterus was anteverted and bulky in size measuring 89\*53\*39mm and showed a small intramural anterior wall fibroid measuring 13\*15mm. Haemoglobin- 10.3gm%, ESR- 10mm/dl

### Diagnosis

The clinical features along with the ultrasound scan report suggests that it is case of Intramural fibroid and was diagnosed as

*Garbhashyagata* (intrauterine) *Granthi* (encapsulated growth). Based on the symptoms, it was treated on the lines of Pradara (Menorrhagia) and Granthi.

## Therapeutic interventions

Based on Ayurvedic line of management of Asrigdhara (menorrhagia) & Rajodosha (menstrual disorders) and granthi (tumour) and the clinical experience, we formulated the line of treatment from medicines available at OPD. She was advised the following medicines initially for a period of 3months to observe changes in the menstrual cycle (Table 1).

The treatment was scheduled initially for 3months with a follow up once in 15days, however it was extended for next 6months with the supportive results and interest of the patient, till the patient was completely relieved of symptoms. Patient was observed for a period of 6 months without any medications (Table 2).

**Table 1** Therapeutic interventions

S. No	Medicine	Dosage	Time of administration
1	Ashokarishta*	15ml twice daily	After food
2	Chandraprabhavati*	1 Tab twice daily	After food
3	Pushyanugachurna tabs*	2 Tab twice daily	After food
4	Polyherbal syrup**	10ml twice daily	After food

Source of medicines

\*Indian Medicines Pharmaceutical Corporation Limited, India

\*\*Solumiks herbals limited

**Table 2** Changes in subjective and objective criteria before and after treatment

	Subjective criteria			
	Before treatment	After treatment	Follow up scan	
Menorrhagia	Present	Absent	Absent	
Duration of the menstrual cycle	7-8days	3-4days	3-4days	
Fatigue	+++	-	-	
	Objective criteria			
	Size of uterus	89*53*39mm	53*36*43mm	77*46*39mm
	Size of the fibroid in Ultrasound scan	13*15 mm	7*4mm	No fibroid
	Timeline	Nov. 2015	Sept 2016	Sept 2017

## Discussion

Fibroids also known as Uterine leiomyomas (fibroids or myomas) are benign tumours of the human uterus, and the single most common indication for hysterectomy.<sup>2</sup> About 20% to 80% of women develop fibroids by the age of 50. In 2013, it was estimated that 171million women were affected worldwide. After menopause, they usually decrease in size. However, the management of fibroids is undergoing an important evolution, with the focus on patient's quality of life. Spies et al.<sup>7</sup> showed that symptomatic uterine fibroids can have a negative

impact on health related quality of life (HRQL) through impairment of daily activities and anxiety, which may develop before and after diagnosis.<sup>7</sup> Patients report psychological distress, helplessness in dealing with the diagnosis and treatment options, negative body image, effects on sexuality and a lack of support.<sup>8</sup>

Accordingly, surgical techniques and aggressive treatments are reserved for only those cases with heavy symptomatology, while the clinical diagnosis based on size and number of fibroids remains in a second plane in this situations.<sup>9</sup> In this case the patient opted for

Ayurvedic treatment instead of surgery as hysterectomy would have long term complications like osteoporosis.

According to Ayurveda, Uterine fibroid is considered as *Garbhashyagata* (intrauterine) *Granthi* (encapsulated growth). The symptoms are similar to the condition “pradara” which is menorrhagia. Treatment was aimed at reduction of symptoms of menorrhagia as well as treating the fibroid. It is based on the Ayurvedic principles of karyakaranabhava (Cause and effect theory). When the effect is treated, it should have an impact on its causative factors also. It has been observed that fibroids have reduced to half its size by the end of 6 months of treatment and fully disappeared later.

Ashokarishta, is a popular polyherbal Ayurvedic medicine mentioned in the classical text Bhaishajya Ratnavali in the context of Stree-roga (Gynecology).<sup>10</sup> It is extensively used in the condition Pradara/Raktapradara/Asrukdhara (as mentioned in Ayurveda) which is characterized by qualitative and quantitative increase in flow of menstrual bleeding. It mainly contains medicinal plants like *Ashoka* (*Saraca indica* Linn), *Amalaki* (*Embolia officinalis* Gaertn), *Bibhitaki* (*Terminalia bellerica*), *Jeeraka* (*Cuminum cyminum* Linn), *Haritaki* (*Terminalia chebula* Retz.), *Shunti* (*Zingiber officinalis* Rosc), *Amra* (*Mangifera indica* Linn), *Vasa* (*Adhatoda vasica*), *Chandana* (*Santalum album*), *Daruharidra* (*Berberis aristata* DC), *Dhataki* (*Woodfordia fruticosa* L.) KURZ), *Musta* (*Cyperus rotundus* Linn), *Kamala* (*Nymphaea nouchali* BURM. F.), and *Guda* (*Jaggery*). It contains 5–10 % of self-generated alcohol, which acts as a medium for herbal active principles. *Ashoka* contains mainly tannins, saponins,  $\beta$ -sitosterol and exhibits anti-oxidant, anti-inflammatory activities, hence indicated in Uterine bleeding.<sup>11</sup> It has both antioxidant and Hematoprotective potentials which is essentially needed for management of menorrhagia.<sup>12</sup> *Ashoka* bark contains phenol glycoside which has direct effect on uterine musculature. It stimulates both endometrium and ovarian tissue. It decreases blood flow and tones up the endometrial vascularity and thus, checks excessive bleeding.<sup>13</sup>

Pushyanuga churna is mentioned in classical Ayurvedic text Charaka Samhita in the context of gynecological disorders.<sup>14</sup> It contains medicinal plants like *Pata* (*Cissampelos pareira* L.), *Jambu* (*Syzygium cumini* L.) SKEELS), *Amra* (*Mangifera indica* L.), *Pashana bheda* (*Aerva lanata* L.) JUSS. EX SCHULT, *Daruharidra* (*Berberis aristata* DC), *Shalmali* (*Bombax ceiba* L.), *Kamala* (*Nymphaea nouchali* BURM. F.), *Kumkuma* (*Crocus sativus* L.), *Ativisha* (*Aconitum heterophyllum* WALL. EX ROYLE), *Musta* (*Cyperus rotundus* Linn), *Bilva* (*Aegle marmelos* L.) CORREA EX SCHULTZ), *Lodhra* (*Symplocos racemosa*), *Rakta chandana* (*Pterocarpus santalinus* L.F.), *Kutaja* (*Holarrhena pubescens* (BUCH.-HAM.) WALLICH EX DO), *Dhataki* (*Woodfordia fruticosa* L.) KURZ), *Yastimadhu* (*Glycyrrhiza glabra* L.), *Arjuna* (*Terminalia arjuna* (ROXB.) WIGHT & ARN) and other drugs. It is also indicated in Asrigdhara (Menorrhagia, Metrorrhagia and other gynecological disorders).<sup>15</sup> Pushyanugachurna acts as uterine tonic, menstrual regulator and astringent i. e. vasoconstrictive in action.<sup>16</sup>

Chandraprabhavati is a herbomineral Ayurvedic formulation indicated in Stree-roga (Gynaecological disorders), ArtavaRuja (Dysmenorrhoea) and other genitourinary disorders. It mainly contains Shilajathu (Bitumen) and Guggulu (Commiphora mukul) which exert scraping action, thereby help in reduction of fibroid. Lohabhasma (Ferrous compound) and Makshika (Copper pyrite) helps in balancing hematopoietic component.<sup>17</sup>

Poly herbal syrup also contains drugs *Ashoka*, *Lodhra* etc., the action of which are explained earlier. Most fibroids do not require treatment unless they are causing symptoms to the patient. After menopause, fibroids shrink, and it is unusual for them to cause problems. Symptomatic Management is mostly indicated except in extreme cases where invasive procedures or surgery is opted. In the present case, whether intramural fibroids are to be treated or not, was a major question. As per the study by Mayra J Thompson et al 2016, it is reported in the literature the need to manage intramural myomas and to treat them appropriately.<sup>18</sup> As the size of the fibroid was 13\*15mm, it could have been self-limiting, but for the bothering symptoms of menorrhagia. Hence, it was decided to administer the Ayurvedic medicines available in the Outpatient department such as *Ashokarishta*, *Pushyanuga churna* & *Chandraprabhavati*.

## Conclusion

Surgical intervention need not be the only management for uterine fibroids. This case illustrates a situation where methodical Ayurvedic intervention can not only help in relieving symptoms but also restores fertility of the women and avoid further complications and successful management.

## Acknowledgements

Authors are grateful to Director General, Central Council of Research in Ayurvedic Sciences for his constant support and encouragement.

## Conflicts of interest

Author declares that there are no conflicts of interest towards the article.

## References

- Munusamy MM, Sheelaa WG, Lakshmi VP. Clinical presentation and prevalence of uterine fibroids: a 3-year study in 3-decade rural South Indian women. *Int J Reprod Contracept Obstet Gynecol.* 2017;6(12):5596–601.
- Stewart EA. Uterine fibroids. *Lancet.* 2001;357(9252):293–298.
- Marsh EE, Al-Hendy A, Kappus D, et al. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. *Women J Womens Health (Larchmt).* 2018;27(11):1359–1367.
- Moravek MB, Bulun SE. Endocrinology of Uterine Fibroids: Steroid Hormones, Stem Cells, and Genetic Contribution. *Curr Opin Obstet Gynecol.* 2015;27(4):276–283.
- El-Balat A, DeWilde RL, Schmeil I, et al. Modern Myoma Treatment in the Last 20years: A Review of the Literature. *Biomed Res Int.* 2018;4593875.
- Kamini Dhiman Ayurvedic intervention in the management of uterine fibroids: A Case series. *Ayu.* 2014;35(3):303–308.
- Spies JB, Coyne K, Gwaou NG. The UFS QOL, a new disease specific symptom and health related quality of life questionnaire for leiomyomata. *Obstet Gynecol.* 2002;99(2):290–300.
- Knudsen NI, Wernecke KD, Siedentopf F, et al. Fears and Concerns of Patients with Uterine Fibroids – a Survey of 807 Women. *Geburtshilfe Frauenheilkd.* 2017;77(9): 976–983.
- Mas A, Tarazona M, Dasi Carrasco J, et al. Updated approaches for management of uterine fibroids. *Int J Womens Health.* 2017;9:607–617.

10. Anonymus. Ayurvedic Formulary of India, Part– I, Part A, 1:5 Ashokarishta, (Bhaishajyaratnavali Strirogadhikara). 2nd edn. New Delhi, India: Ministry of Health and Welfare; 2003. p. 8.
11. Gahlaut A, Shirolkar A, Hooda V, et al.  $\beta$ -sitosterol in different parts of *Saraca asoca* and herbal drug ashokarishta: Quali–quantitative analysis by liquid chromatography–mass spectrometry. *J Adv Pharm Technol Res.* 2013;4(3):146–150.
12. Dubey CK, Meena AK, Mishra V, Singh P, Bansode FW and Singh RK: Antioxidant and Haematoprotective Activity of the *Saraca Indica* Stem Bark. *Int J Pharm Sci Res.* 2015;6(4):1430–1437.
13. Nadkarni KM. Indian Materia Medica, Vol–1, 3<sup>rd</sup> end. India: Bombay Popular Prakashan; 1982, p. 1105.
14. Sharma PV. CharakaSamhita of Agnivesha's. Chikitsa Sthana, Chapter 30. Varanasi: Chowkhamba Sanskrit Series Office; 1980.
15. Anonymous. Ayurvedic Pharmacopia of India. India: Bhaishajya Ratnavali, Streeroga adhikara; 2008. p. 46–49.
16. Bhuvaneswari M, Seetarama K. Role of Pushyanuga Churna in Rakta Pradara. *IAMJ.* 2017;5(12):4465–4468.
17. Ministry of Health and Family Welfare. Ayurvedic Formulary of India–part I–part a formulation. 2<sup>nd</sup> edn. India: Ministry of Health and Family Welfare; 2016. p. 512–515.
18. Thompson MJ, Carr BR. Intramural myomas: to treat or not to treat. *Int J Womens Health.* 2016;8:145–149.